No Data
No Data
Shanghai OPM Biosciences Co., Ltd.'s (SHSE:688293) Stock Price Dropped 9.1% Last Week; Private Equity Firms Would Not Be Happy
Key Insights Shanghai OPM Biosciences' significant private equity firms ownership suggests that the key decisions are influenced by shareholders from the larger public The top 4 shareholders own 52%
OPM Biosciences' Shareholder to Cut Stake
Shenzhen Dachen Chuanglian Equity Investment Fund Partnership (Limited Partnership) plans to reduce its holdings in Shanghai OPM Biosciences (SHA:688293), the company said in a Thursday filing on the
Oppo Mai (688293.SH): Dachen Chuanglian plans to reduce holdings by no more than 300,000 shares
On May 8, Ge Longhui (688293.SH) announced that it received the “Notice Letter on the Share Reduction Plan” from Dachen Chuanglian, the shareholder of the company. Due to the shareholders' own capital requirements, Dachen Chuanglian plans to reduce the company's shares by 300,000 shares through centralized bidding, accounting for 0.26% of the company's total share capital.
Opmax (688293.SH): Has repurchased a total of 0.9207% of the company's shares
Gelonghui (688293.SH) announced on May 6, 2024, that as of April 30, 2024, the company had repurchased 1,056,703 shares of the company through centralized bidding transactions, accounting for 0.9207% of the company's current total share capital of 114,772,460 shares. The highest transaction price was 58.00 yuan/share, the minimum transaction price was 29.88 yuan/share, and the total transaction amount was 46,605,916.14 yuan (not including transaction fees such as trading commissions).
Oppo Mai (688293.SH): Proposed integration of CDMO business
On April 28, Gelonghui (688293.SH) announced that the company plans to integrate the CDMO business, increase the capital of its wholly-owned subsidiary Shanghai Silun Biotechnology Co., Ltd. (“Silun Biotech”), and transfer assets related to the CDMO business belonging to the company and its wholly-owned subsidiary Shanghai Opumai Biotechnology Co., Ltd. to Silun Biotech to fully utilize the “Silun Biotech” brand effect and enhance the competitiveness of the company's CDMO business. After the capital increase is completed, Silun Biotech is still a wholly-owned subsidiary of Opmax. This asset transfer will not cause changes in the scope of the company's consolidated statements and is not involved
Oppo Mai (688293.SH) reported 2023 annual results, with net profit of 54.085 million yuan, a year-on-year decrease of 48.72%
According to the Zhitong Finance App, Oppo Mai (688293.SH) released its 2023 annual report, with revenue of 243 million yuan, a year-on-year decrease of 17.41%. Net profit attributable to shareholders of listed companies was 54.085 million yuan, a year-on-year decrease of 48.72%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was RMB 347.24,900, a year-on-year decrease of 60.89%. Basic earnings per share were $0.47. A cash dividend of RMB 2.30 (tax included) is distributed to all shareholders for every 10 shares.
No Data